Icosavax announced Wednesday the close of $100 million in Series B financing.

The funds will support the development of the biotech’s bivalent RSV and human metapneumovirus vaccine through initial clinical studies, continued evaluation of its virus-like particle (VLP) Covid-19 vaccine candidate, and expansion of its pipeline of other VLP vaccine candidates targeting respiratory diseases, the press release said.

Three companies have reported promising early vaccine trial results.

Massachusetts-based Moderna Therapeutics announced in an interim Phase 1 report this week that its human metapneumovirus and parainfluenza type 3 combo vaccine, mRNA-1653, boosted serum neutralization titers against the two pathogens. No vaccines exist for either hMPV or PIV3.

Meanwhile, San Francisco‑based Vaxart reported during its Q4 financial call last week that it plans to start Phase 1 bivalent and Phase 2…